Anthracyclines and Related Substances

DrugDrug NameDrug Indication
DB00385ValrubicinFor the treatment of cancer of the bladder.
DB00445EpirubicinFor use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
DB00694DaunorubicinFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
DB00997DoxorubicinDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
DB01177IdarubicinFor the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
DB01204MitoxantroneFor the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
DB06193PixantroneCurrently in Phase III investigation for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who have failed two prior lines of therapy. Presently, no standard therapy exists for patients with relapsed or refractory NHL. [2] After first line therapy has been initiated, most patients have received their lifetime limit of doxorubicin and further use of anthracyclines may potentially lead to anthracycline-induced congestive heart failure (CHF). Pixantrone is an attractive alternative as a second line agent, due to its lack of cardiac toxicity. [2] The phase III trial, PIX-R, is ongoing and will compare pixantrone multidrug therapy with an equivalent regimen in patients with diffuse large B-cell lymphoma (the most common type of NHL). Previous study results have also suggested the possibility that pixantrone may be safe and effective in doxorubicin naive patients. In myocardial strips which are doxorubicin naive, pixantrone is taken up to a higher degree than in myocardial strips which are doxorubicin exposed, and once absorbed exhibits redox inactivity. [3] Pixantrone dimaleate has also been investigated as a treatment for acute myelogenous leukemia, diffuse large B-cell lymphoma, follicular lymphoma, metastatic breast cancer, low grade small lymphocytic lymphomas and general metastatic cancers.
DB06263AmrubicinInvestigated for use/treatment in lung cancer [A4138].
DB11616PirarubicinNot Available
DB11617AclarubicinNot Available
DB11618ZorubicinNot Available
DrugDrug NameTargetType
DB00385ValrubicinDNA topoisomerase 2-alphatarget
DB00445EpirubicinChromodomain-helicase-DNA-binding protein 1target
DB00445EpirubicinDNA topoisomerase 2-alphatarget
DB00445EpirubicinMultidrug resistance-associated protein 1transporter
DB00445EpirubicinUDP-glucuronosyltransferase 2B7enzyme
DB00445EpirubicinCytosolic phospholipase A2enzyme
DB00694DaunorubicinXanthine dehydrogenase/oxidaseenzyme
DB00694DaunorubicinCytochrome P450 3A5enzyme
DB00694DaunorubicinNADPH--cytochrome P450 reductaseenzyme
DB00694DaunorubicinMultidrug resistance protein 1transporter
DB00694DaunorubicinMultidrug resistance-associated protein 1transporter
DB00694DaunorubicinCanalicular multispecific organic anion transporter 1transporter
DB00694DaunorubicinMultidrug resistance-associated protein 6transporter
DB00694DaunorubicinBile salt export pumptransporter
DB00694DaunorubicinMultidrug resistance-associated protein 7transporter
DB00694DaunorubicinATP-binding cassette sub-family G member 2transporter
DB00694DaunorubicinDNA topoisomerase 2-alphatarget
DB00694DaunorubicinDNA topoisomerase 2-betatarget
DB00694DaunorubicinCytochrome P450 1A1enzyme
DB00694DaunorubicinCytochrome P450 1B1enzyme
DB00694DaunorubicinCytochrome P450 3A4enzyme
DB00997DoxorubicinDNA topoisomerase 2-alphatarget
DB00997DoxorubicinCytochrome P450 3A4enzyme
DB00997DoxorubicinCytochrome P450 2D6enzyme
DB00997DoxorubicinCytochrome P450 2B6enzyme
DB00997DoxorubicinMultidrug resistance protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 2transporter
DB00997DoxorubicinMultidrug resistance-associated protein 6transporter
DB00997DoxorubicinMultidrug resistance-associated protein 1transporter
DB00997DoxorubicinMultidrug resistance-associated protein 7transporter
DB00997DoxorubicinATP-binding cassette sub-family G member 2transporter
DB00997DoxorubicinBile salt export pumptransporter
DB00997DoxorubicinSolute carrier family 22 member 16transporter
DB00997DoxorubicinATP-binding cassette sub-family B member 8, mitochondrialtransporter
DB00997DoxorubicinCytochrome P450 1B1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 1enzyme
DB00997DoxorubicinCarbonyl reductase [NADPH] 3enzyme
DB00997DoxorubicinAlcohol dehydrogenase [NADP(+)]enzyme
DB00997DoxorubicinAldo-keto reductase family 1 member C3enzyme
DB00997DoxorubicinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00997DoxorubicinXanthine dehydrogenase/oxidaseenzyme
DB00997DoxorubicinNitric oxide synthase, endothelialenzyme
DB00997DoxorubicinNitric oxide synthase, inducibleenzyme
DB00997DoxorubicinNitric oxide synthase, brainenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrialenzyme
DB00997DoxorubicinNADH dehydrogenase [ubiquinone] iron-sulfur protein 7, mitochondrialenzyme
DB00997DoxorubicinNADPH--cytochrome P450 reductaseenzyme
DB00997DoxorubicinRalA-binding protein 1transporter
DB00997DoxorubicinCanalicular multispecific organic anion transporter 1transporter
DB00997DoxorubicinSerum albumincarrier
DB00997DoxorubicinNucleolar and coiled-body phosphoprotein 1target
DB01177IdarubicinDNA topoisomerase 2-alphatarget
DB01177IdarubicinMultidrug resistance-associated protein 1transporter
DB01177IdarubicinCytochrome P450 2C9enzyme
DB01177IdarubicinCytochrome P450 2D6enzyme
DB01204MitoxantroneDNA topoisomerase 2-alphatarget
DB01204MitoxantroneCytochrome P450 2E1enzyme
DB01204MitoxantroneMultidrug resistance protein 1transporter
DB01204MitoxantroneMultidrug resistance-associated protein 1transporter
DB01204MitoxantroneATP-binding cassette sub-family G member 2transporter
DB01204MitoxantroneCytochrome P450 1B1enzyme
DB01204MitoxantroneCytochrome P450 3A4enzyme
DB06263AmrubicinDNA topoisomerase 2-alphatarget
DB06263AmrubicinNADPH--cytochrome P450 reductaseenzyme
DB06263AmrubicinCarbonyl reductase [NADPH] 1enzyme
DB06263AmrubicinATP-binding cassette sub-family B member 5transporter